BR0315867A - Composições e métodos para terapia transdérmica com oxibutinina - Google Patents

Composições e métodos para terapia transdérmica com oxibutinina

Info

Publication number
BR0315867A
BR0315867A BR0315867-5A BR0315867A BR0315867A BR 0315867 A BR0315867 A BR 0315867A BR 0315867 A BR0315867 A BR 0315867A BR 0315867 A BR0315867 A BR 0315867A
Authority
BR
Brazil
Prior art keywords
oxybutynin
compositions
therapy
methods
adverse drug
Prior art date
Application number
BR0315867-5A
Other languages
English (en)
Inventor
Steven W Sanders
Charles D Ebert
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312070&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0315867(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Publication of BR0315867A publication Critical patent/BR0315867A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00646—Medication patches, e.g. transcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA TERAPIA TRANSDéRMICA COM OXIBUTININA". A presente invenção refere-se a composições e métodos para administrar oxibutinina enquanto minimiza a incidência e/ou gravidade de experiências adversas com droga associadas à terapia com oxibutinina. Em um aspecto, essas composições e métodos proporcionam uma menor concentração plasmática de metabólitos de oxibutinina, tal como N-desetiloxibutinina, que se presume estar contribuindo pelo menos em parte para algumas das experiências adversas com droga, enquanto mantém concentração plasmática de oxibutinina suficiente para beneficiar um indivíduo com terapia de oxibutinina. A invenção também se refere a isómeros de oxibutinina e seus metabólitos que satisfazem essas características de incidência e/ou gravidade minimizadas de experiências adversas com droga, e manutenção de terapia benéfica e eficaz para bexiga superativa. Em alguns aspectos, as composições poderão se apresentar na forma de um gel administrado topicamente de forma desobstruída ou livre.
BR0315867-5A 2002-11-01 2003-10-31 Composições e métodos para terapia transdérmica com oxibutinina BR0315867A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/286,381 US7029694B2 (en) 2000-04-26 2002-11-01 Compositions and methods for transdermal oxybutynin therapy
PCT/US2003/034654 WO2004041188A2 (en) 2002-11-01 2003-10-31 Compositions and methods for transdermal oxybutynin therapy

Publications (1)

Publication Number Publication Date
BR0315867A true BR0315867A (pt) 2005-09-27

Family

ID=32312070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315867-5A BR0315867A (pt) 2002-11-01 2003-10-31 Composições e métodos para terapia transdérmica com oxibutinina

Country Status (16)

Country Link
US (1) US7029694B2 (pt)
EP (4) EP2612629B1 (pt)
JP (4) JP2006513161A (pt)
KR (4) KR20110043725A (pt)
CN (2) CN1708269A (pt)
AU (2) AU2003287377B2 (pt)
BR (1) BR0315867A (pt)
CA (2) CA2718277C (pt)
DK (1) DK1565136T3 (pt)
ES (2) ES2532495T3 (pt)
MX (1) MXPA05004110A (pt)
NO (2) NO339626B1 (pt)
NZ (2) NZ539562A (pt)
RU (1) RU2311170C2 (pt)
WO (1) WO2004041188A2 (pt)
ZA (1) ZA200503316B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US7101566B2 (en) * 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
WO2004024187A2 (en) * 2002-09-13 2004-03-25 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
CN100569210C (zh) * 2003-05-07 2009-12-16 弗门尼舍有限公司 具有改善的香气持久力的可喷洒香料
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
TW200512013A (en) * 2003-09-18 2005-04-01 Orient Europharma Co Ltd Gel formulation of oxybutynin hydrochloride
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) * 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
JP5815915B2 (ja) * 2005-10-11 2015-11-17 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
NZ571460A (en) * 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
WO2009150408A2 (en) * 2008-06-13 2009-12-17 Summit Corporation Plc Topical antimuscarinic formulations
WO2010008995A2 (en) * 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CN101564377A (zh) * 2009-04-24 2009-10-28 杭州锐思医药科技有限公司 奥昔布宁透皮凝胶及其制备方法
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
EP3141246A1 (en) 2009-08-31 2017-03-15 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
CN102309447A (zh) * 2010-07-06 2012-01-11 上海现代药物制剂工程研究中心有限公司 含盐酸奥昔布宁的自粘性喷雾透皮组合物及制备方法
US11083696B2 (en) * 2011-09-21 2021-08-10 University College Cardiff Consultants Limited Dispersion anaesthetic device
US20140271796A1 (en) * 2011-10-26 2014-09-18 Hisamitsu Pharmaceutical Co., Inc. Oxybutynin-containing transdermal absorption preparation
JP2015510893A (ja) * 2012-03-14 2015-04-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
CN102614108B (zh) * 2012-04-16 2013-10-16 上海现代药物制剂工程研究中心有限公司 含奥昔布宁的立方水质液晶凝胶经皮吸收制剂及其制法
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
EP4122460A1 (en) 2015-01-09 2023-01-25 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
KR101937072B1 (ko) * 2015-04-30 2019-01-09 히사미쓰 세이야꾸 가부시키가이샤 다한증 치료용 외용제
CN108495654B (zh) * 2016-02-25 2022-10-25 久光制药株式会社 外用液剂
WO2018063876A1 (en) * 2016-09-30 2018-04-05 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery systems comprising cetirizine dihydrochloride
US11033511B2 (en) * 2017-08-01 2021-06-15 Hisamitsu Pharmaceutical Co., Inc. Pharmaceutical patch
WO2022045200A1 (ja) * 2020-08-28 2022-03-03 久光製薬株式会社 多汗症治療用の外用液剤

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147236A (en) * 1874-02-10 Improvement in devices for riveting the teeth of saws
US161044A (en) * 1875-03-23 Improvement in combined shovels and ash-pan lifters
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
JPS6025045B2 (ja) 1980-03-19 1985-06-15 製鉄化学工業株式会社 塩水吸収能のすぐれたアクリル酸重合体の製造方法
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US5641504A (en) * 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
EP0481007B1 (en) * 1989-06-07 1997-01-22 BAZZANO, Gail S SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids
US5922342A (en) * 1990-10-01 1999-07-13 Pharmacia & Upjohn Company Lateral edge coated controlled release pharmaceutical compositions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5227169A (en) * 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) * 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
PT100502A (pt) 1991-05-20 1993-08-31 Alza Corp Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
DE69326848T2 (de) * 1992-05-13 2000-01-27 Alza Corp Oxybutynin zur transdermalen Verabreichung
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0721348B1 (en) 1993-09-29 1999-09-01 Alza Corporation Monoglyceride/lactate ester permeation enhancer
MX9603667A (es) * 1994-03-07 1997-06-28 Theratech Inc Dispositivo de suministro transdermico compuesto adhesivo que contiene droga.
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
NL9401051A (nl) * 1994-06-24 1996-02-01 Stichting Tech Wetenschapp Microfoon op basis van fluidum-stroommeting en akoestische generator gebaseerd daarop.
US5840338A (en) 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
KR100209469B1 (ko) * 1994-10-05 1999-07-15 나까도미 히로다카 N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형 제제
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
DE19511698C1 (de) 1995-03-30 1996-08-22 Schober Werkzeug & Maschbau Vorrichtung zum Verbinden einer Siegelfolie mit einer Materialbahn
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5759583A (en) * 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
PT1238660E (pt) * 1996-02-02 2005-10-31 Alza Corp Distribuicao sustentada de um agente activo utilizando um sistema implantavel
JPH09255565A (ja) * 1996-03-26 1997-09-30 Daikyo Yakuhin Kogyo Kk 皮膚局所麻酔用ヒドロゲルパッチ
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5762953A (en) * 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CN1231593A (zh) 1996-10-30 1999-10-13 瑟垃技术有限公司 作为渗透促进剂的乳酸盐的脂肪酸酯
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
NZ500018A (en) * 1997-03-31 2001-07-27 Alza Corp Diffusional implantable delivery system with capillary tube of cross-sectional area and length to deliver beneficial agent
WO1998043555A1 (en) * 1997-04-03 1998-10-08 Point Biomedical Corporation Intravesical drug delivery system
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
US5905391A (en) 1997-07-14 1999-05-18 Intel Corporation Master-slave delay locked loop for accurate delay or non-periodic signals
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
KR100648536B1 (ko) * 1997-11-10 2006-11-24 셀러지 파마세우티칼스, 인크 침투 보강 및 자극 감소를 위한 계
DE29823343U1 (de) * 1998-03-20 1999-07-15 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Oxybutynin enthaltend
AR018321A1 (es) 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
FR2779438B1 (fr) * 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
JP2003532629A (ja) * 1999-09-08 2003-11-05 ワトソン ファーマシューティカルズ， インコーポレイテッド 第４アンモニウム塩の経皮薬剤放出への使用
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
WO2001080796A1 (en) * 2000-04-26 2001-11-01 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US6545046B2 (en) 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
JP5039252B2 (ja) * 2000-08-31 2012-10-03 ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー 性機能低下を治療するための医薬組成物及び方法
US9875202B2 (en) 2015-03-09 2018-01-23 Nordic Semiconductor Asa Peripheral communication system with shortcut path

Also Published As

Publication number Publication date
KR20050061588A (ko) 2005-06-22
JP6118358B2 (ja) 2017-04-19
ES2764081T3 (es) 2020-06-02
CA2504021C (en) 2013-08-13
CA2718277C (en) 2015-02-03
ES2532495T3 (es) 2015-03-27
AU2010200418A1 (en) 2010-02-25
DK1565136T3 (da) 2015-04-20
EP1565136A4 (en) 2010-12-22
NZ539562A (en) 2008-11-28
US7029694B2 (en) 2006-04-18
AU2003287377B2 (en) 2010-02-25
NZ586108A (en) 2011-09-30
JP5770582B2 (ja) 2015-08-26
US20030147926A1 (en) 2003-08-07
JP2006513161A (ja) 2006-04-20
KR20120038026A (ko) 2012-04-20
MXPA05004110A (es) 2005-06-22
JP2017031191A (ja) 2017-02-09
JP2012046526A (ja) 2012-03-08
WO2004041188A2 (en) 2004-05-21
JP6209263B2 (ja) 2017-10-04
CN101904812A (zh) 2010-12-08
EP3659562A1 (en) 2020-06-03
RU2311170C2 (ru) 2007-11-27
EP1565136A2 (en) 2005-08-24
EP2612629B1 (en) 2019-12-04
KR20130026510A (ko) 2013-03-13
CN1708269A (zh) 2005-12-14
EP2606865A1 (en) 2013-06-26
CA2504021A1 (en) 2004-05-21
NO339626B1 (no) 2017-01-16
WO2004041188A3 (en) 2004-10-28
CA2718277A1 (en) 2004-05-21
AU2003287377A1 (en) 2004-06-07
KR20110043725A (ko) 2011-04-27
EP1565136B1 (en) 2015-02-25
JP2015131826A (ja) 2015-07-23
NO20052625L (no) 2005-05-31
NO20161918A1 (no) 2005-05-31
ZA200503316B (en) 2006-08-30
RU2005116678A (ru) 2005-12-10
EP2612629A1 (en) 2013-07-10
AU2010200418B2 (en) 2012-06-14
NO343756B1 (no) 2019-06-03

Similar Documents

Publication Publication Date Title
BR0315867A (pt) Composições e métodos para terapia transdérmica com oxibutinina
MX342305B (es) Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina.
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
MX2020009246A (es) Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular.
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
BR0307975A (pt) Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina
NO20056252L (no) Terapeutiske og profylaktiske metoder for neuromuskulaere lidelser
AR054234A1 (es) Composicion farmaceutica para el tratamiento del cancer
MX2009013989A (es) Terapia en combinacion para depresion.
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BRPI0515600A (pt) formas farmacêuticas opióides tendo cmédia e auc em estado estável proporcionais à dose e cmax de dose única inferior ao proporcional à dose
BR0209948A (pt) Inibidores de fator inibitório de migração de macrófago e métodos para identificar os mesmos
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo
BR9914419A (pt) Terapia para melhoria da percepção
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR119158A1 (es) Tratamientos de angioedema hereditario
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios
CL2016001707A1 (es) Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11).
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
BR0315346A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a
BR112014030777A2 (pt) método e composição para aliviar sintomas de tumor
BR112021018973A2 (pt) Formulação de combinação tripla de baixa dose

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61F 13/00

Ipc: A61K 9/00 (2006.01), A61K 31/216 (2006.01), A61P 1

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]